CNBC's Meg Tirrell on why these two stocks are taking such a beating today. » Read More
U.S. Surgeon General Vivek Murthy told CNBC he was "deeply disturbed" when he heard about Mylan's price increase of its device EpiPen.
The only way to stop drug companies from jacking up the costs of live-saving treatments is through price controls, a former Obama health advisor says.
Dr. Ezekiel Emanuel, University of Pennsylvania Chair of Medical Ethics & Health Policy, weighs in on the drug pricing debate in the wake of Mylan's EpiPen pricing saga.
Brian Stutland, Equity Armor Investments CIO, shares his bullish take on the health care sector, amid all the political rhetoric surrounding Mylan. The "Fast Money" traders weigh in.
CNBC senior markets commentator Mike Santoli; and Susan Ochs, New America Foundation, discuss Mylan CEO Heather Bresch and the company's release of a generic EpiPen.
CNBC's Meg Tirrell reports on Mylan's decision to create a "generic" of its own product, the Epipen.
CNBC's Meg Tirrell reports that a House committee has sent a letter to Mylan for information on the EpiPen price increase.
Former FDA Deputy Commissioner Dr. Scott Gottlieb, who's with the American Enterprise Institute, discusses what's wrong with the US health care system.
It's not just greed that makes companies like Mylan charge outrageous prices for drugs, explains former FDA official Scott Gottlieb.
Steve Brill, lawyer and author of "America's Bitter Pill: Money, Politics, Backroom Deals and the Fight to Fix our Broken Healthcare System" discusses what can be done to make things right with America's health care system.
CNBC's Meg Tirrell reports on Mylan's decision to launch a generic EpiPen as a way of cutting the cost of the treatment.
Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
Some are questioning whether Mylan's generic EpiPen may net the drugmaker more revenue than the original version.
Jim Cramer said Monday price adjustments from EpiPen's owner Mylan can be attributed to the rise of vocal social media platforms such as Twitter.
Mylan says the health-care system is to blame for families having to pay more for life-saving drugs like EpiPen and Joe Minarik says, sadly, that’s pretty much true.
There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC.
Get the best of CNBC in your inbox